GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

South San Francisco, California, UNITED STATES

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15 and May 17-21.

Details of the abstract and poster presentation are as follows:

Title: Single cell transcriptomics reveals the effect of PD-L1 and TGF-β blockade on the tumor microenvironment
Presenter: Erica Stone, Ph.D., vice president of Oncology
Session Category: Tumor Biology
Session Title: Chemokines in the Tumor Microenvironment
Poster Number: 2684
Presentation Type: E-poster
Date and Time: Links to the poster presentation will be available on the conference website beginning at 8:30 a.m. EDT on Saturday, April 10 and questions or meeting requests can be sent directly through that page. Posters will be available for viewing to meeting registrants until Monday, June 21.

A major goal in oncology is to find strategies, such as dual PD-L1/TGF- β blockade, that enhance T cell infiltration of tumors to improve anti-tumor activity and efficacy of anti-PD-1/PD-L1 therapy. The poster to be presented details transcriptomic effects of PD-L1 and/or TGF- β blockade at the single cell level on cells in the tumor and surrounding microenvironment. It also provides an example of how the data could be further leveraged translationally to identify novel approaches to overcome resistance to first generation immunotherapies, including anti-PD-L1 combination therapy.

For more details, please access the abstract online here.

About Grifols
Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with nearly 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies. Its novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. This approach has enabled the creation of first-in-class recombinant polyclonal antibody therapies for the treatment of infectious diseases, including GigaGen’s lead asset GIGA-2050 for COVID-19. In addition, GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. 

For more information, please visit or

Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications

Grifols Media Press Office 
Tel. +34 571 00 02

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.